0 Table of Contents |
1 Clinical Practice Guidelines (CPG) on EBMonFHIR |
2 Profiles |
3 Code Systems |
4 Value Sets |
5 Extensions |
6 Examples |
7 Downloads |
8 History |
9 Artifacts Summary |
9.1 Cohorts |
9.2 CPGComputablePlanDefinition |
9.3 CPGRecommendationDefinition |
9.4 CPGShareablePlanDefinition |
9.5 CPGStrategyDefinition |
9.6 Eligibility Criteria |
9.7 Outcome Evidence |
9.8 PICO Evidence Variable |
9.9 Recommendation Action |
9.10 Shareable PlanDefinition |
9.11 Assessment Action |
9.12 Body Positioning Action |
9.13 Certainty of Evidence Rating |
9.14 Clinical Practice Guideline |
9.15 Drug Administration Action |
9.16 Evidence Data Set |
9.17 Evidence Synthesis Cohorts |
9.18 Guideline Bundle |
9.19 Guideline Citation |
9.20 Intervention Definition |
9.21 Net Effect Estimate |
9.22 Outcome Definition |
9.23 Outcome Evidence Synthesis |
9.24 Recommendation |
9.25 Recommendation Citation |
9.26 Recommendation Eligibility Criteria |
9.27 Recommendation Justification |
9.28 Recommendation Plan |
9.29 Study Citation |
9.30 Study Cohort |
9.31 Study Eligibility Criteria |
9.32 Study Outcome Evidence |
9.33 Action Combination Method |
9.34 ArtifactAssessment Publication Status |
9.35 ArtifactAssessment Version |
9.36 CQFM Artifact Comment |
9.37 Dosage Condition |
9.38 qualityOfEvidence |
9.39 strengthOfRecommendation |
9.40 Action Combination Method |
9.41 Action Selection Behavior Required |
9.42 Allergic Disposition SCT |
9.43 Assessment |
9.44 Assessment Scales |
9.45 Body Positioning SNOMED CT |
9.46 Clinical Importance of Outcome |
9.47 Cochrane PICO |
9.48 Cochrane PICO Intervention |
9.49 Cochrane PICO Outcome |
9.50 Cochrane PICO Population |
9.51 Episode Of Care Type |
9.52 Guideline Recommendation Status |
9.53 Guideline Stage Classification |
9.54 Laboratory Observations |
9.55 Mean Difference Type |
9.56 Radiologic Finding SCT |
9.57 Rating Acceptability |
9.58 Rating Benefit And Harms |
9.59 Rating Certainty Of Evidence |
9.60 Rating Concern Degree |
9.61 Rating Consensus |
9.62 Rating Equity |
9.63 Rating Feasibility |
9.64 Rating Preference And Values |
9.65 Rating Resources |
9.66 Rating Up Rating One Level |
9.67 Rating Up Rating Two Levels |
9.68 Recommendation Strength |
9.69 Relative Effect Type |
9.70 Substances SNOMED CT |
9.71 Ventilation Observable SCT |
9.72 Action Combination Method |
9.73 CEOsys Code System |
9.74 Clinical Importance of Outcome |
9.75 Cochrane Core Ontology |
9.76 Cochrane PICO Ontology |
9.77 Evidence Certainty Rating |
9.78 Evidence To Decision Certainty Rating |
9.79 Evidence To Decision Certainty type |
9.80 Guideline Stage Classification |
9.81 KontaktArtDe |
9.82 Recommendation Strength |
9.83 SynthesisType |
9.84 All-cause mortality |
9.85 Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) e.V |
9.86 Certainty of Evidence for outcome: mortality of Dexamethasone application |
9.87 COVID19 Intensive Care Treatment Guideline |
9.88 COVID19 Intensive Care Treatment Guideline |
9.89 Dexamethasone Application |
9.90 Dexamethasone Application |
9.91 Dexamethasone Application (Intravenous) |
9.92 Dexamethasone Application (Oral) |
9.93 Dexamethasone for critically ill COVID-19 patients |
9.94 Dexamethasone Recommendation |
9.95 Example Assessment Action |
9.96 Example Body Positioning Action |
9.97 Example Certainty Of Evidence Rating |
9.98 Example DrugAdministration Action |
9.99 Example Evidence Data Set |
9.100 Example Evidence Synthesis Cohorts |
9.101 Example Guideline |
9.102 Example Guideline Citation |
9.103 Example Intervention |
9.104 Example Net Effect Estimate |
9.105 Example No DrugAdministration Action |
9.106 Example Organization |
9.107 Example Outcome |
9.108 Example Outcome Evidence Synthesis |
9.109 Example Recommendation Citation |
9.110 Example Recommendation Eligibility Criteria |
9.111 Example Recommendation Justification |
9.112 Example Recommendation plan |
9.113 Example Study Citation |
9.114 Example Study Cohort |
9.115 Example Study Eligibility Criteria |
9.116 Example Study Outcome Evidence |
9.117 Guideline Recommendation Example |
9.118 Mortality Outcome for Dexamethasone application |
9.119 No Dexamethasone Application |
9.120 No dexamethasone application for non-ventilated COVID-19 patients |
9.121 NO Dexamethasone for moderately ill COVID-19 patients |
9.122 Population: COVID19 Non-Ventilated |
9.123 Population: COVID19 Ventilated |
9.124 recommendation |
9.125 Study cohort for Systemic corticosteroids plus standard care vs. standard care (plus/minus placebo) |
9.126 Study eligibility criteria for Systemic corticosteroids plus standard care vs. standard care (plus/minus placebo) |
9.127 Systemic corticosteroids for the treatment of COVID-19 |
9.128 Therapy of hospitalized COVID-19 patients |